Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Aptinyx Got Crushed Today

By Maxx Chatsko - Updated Apr 19, 2019 at 6:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported results for an important phase 2 trial.

What happened

Shares of Aptinyx (APTX -0.48%) fell over 71% today after the company reported phase 2 trial results that missed the mark. Its lead drug candidate, NYX-2925, did not meet the primary endpoint in a study evaluating it as potential treatment for painful diabetic peripheral neuropathy. 

Analysts were watching the mid-stage asset's development because it had the potential to become an abuse-tolerant treatment option for painful diabetic peripheral neuropathy. It's also being evaluated in a phase 2 trial for fibromyalgia. The clinical failure reset the company's market cap from nearly $600 million to around $175 million in just one day.

As of 11:33 a.m. EST, the stock had settled to a 70.4% loss.

A stick figure businessman trying to use a pulley to lift a falling stock chart.

Image source: Getty Images.

So what

Aptinyx has focused its drug development efforts on diseases of the central nervous system. To that end, while NYX-2925 was the most advanced drug candidate in the pipeline, there are two others in development. NYX-783 is ready to begin a phase 2 trial evaluating its potential to treat post-traumatic stress disorder, and NYX-458 is currently being evaluated in a phase 1 trial as a potential treatment for Parkinson's disease. 

All three drug candidates target NMDA receptors found in nerve cells, which help to regulate cognitive function and other biological processes. NMDA receptors have become important targets, along with GABA receptors, among next-generation treatments of central nervous diseases including depression. That could give investors a little optimism that Aptinyx may be on the right track, although it'll be difficult to get too excited without a phase 2 trial success (when the effectiveness of a drug is evaluated).

Now what

If there's any silver lining for investors, it's the fact that Aptinyx reported $165 million in cash and cash equivalents at the end of September 2018. That's a nice chunk of change for a company with relatively light capital requirements (the business reported an operating loss of $40 million in the first nine months of 2018), which provides some flexibility on how to proceed. But whether the company goes all-in on its remaining clinical programs, acquires additional assets, or plucks a promising compound from preclinical studies; investors simply don't have much reason to be invested in the business at this time.

Check out all our earnings call transcripts.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aptinyx Inc. Stock Quote
Aptinyx Inc.
APTX
$0.35 (-0.48%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.